MorphoSys AG Company Update November 2016

MorphoSys AG presented a company update highlighting its diverse partnership network, proprietary antibody libraries and protein optimization platforms, and robust R&D pipeline with 28 antibodies in clinical development. The presentation outlined the company's focus on advancing differentiated therapies for cancer and inflammation, with up to 39 expected clinical read-outs in 2016/2017.